Year None20212020201920182017 Apr 10, 2021 F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster PDF Version Apr 01, 2021 F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration PDF Version Mar 29, 2021 F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update PDF Version Mar 16, 2021 F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021 PDF Version Mar 04, 2021 F-star Therapeutics to Present at Upcoming Investor Conferences PDF Version Jan 20, 2021 F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 PDF Version Jan 06, 2021 F-star Therapeutics to Participate in Upcoming Conferences PDF Version Jan 04, 2021 F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial PDF Version
